Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
The DOI matches its Crossref record; 307 of the 308 references it cites were found in a registry or an index.
Abstract
The acetylation of histone and non-histone proteins has been implicated in several disease states. Modulation of such epigenetic modifications has therefore made histone deacetylases (HDACs) important drug targets. HDAC3, among various class I HDACs, has been signified as a potentially validated target in multiple diseases, namely, cancer, neurodegenerative diseases, diabetes, obesity, cardiovascular disorders, autoimmune diseases, inflammatory diseases, parasitic infections, and HIV. However, only a handful of HDAC3-selective inhibitors have been reported in spite of continuous efforts in design and development of HDAC3-selective inhibitors. In this Perspective, the roles of HDAC3 in various diseases as well as numerous potent and HDAC3-selective inhibitors have been discussed in detail. It will surely open up a new vista in the discovery of newer, more effective, and more selective HDAC3 inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since HDAC3 can directly regulate cell epigenetic landscape that may subsequently reshape transcriptome profiles (8, 12)”
From Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke (2024) · cites this paper as [12]
Citations
Cites
2 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedJanczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183
RetractedAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566
Yang, W.-M., Inouye, C., Zeng, Y., Bearss, D., & Seto, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.12845 · Cited by 546
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 508
HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation
McQuown, S. C., Barrett, R. M., Matheos, D. P., Post, R. J., Rogge, G. A., Alenghat, T., Mullican, S. E., Jones, S., Rusche, J. R., Lazar, M. A., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5052-10.2011 · Cited by 507
Structure of Hdac3 Bound to Co-Repressor and Inositol Tetraphosphate
Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. R. (2012) · Nature · doi:10.1038/nature10728 · Cited by 505
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442
Yang, W.-M., Yao, Y.-L., Sun, J.-M., Davie, J. R., & Seto, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28001 · Cited by 438
Taori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Bhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
Lee, H.-Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, J., Bloomquist, E., Li Shen, Y., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 357
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Distribution of histone deacetylases 1–11 in the rat brain
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686117 · Cited by 347
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration
Sun, Z., Miller, R. A., Patel, R. T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M. J., Unterman, T. G., Shulman, G. I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2744 · Cited by 335
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Chen, S., Ye, J., Chen, X., Shi, J., Wu, W., Lin, W., Lin, W., Li, Y., Fu, H., & Li, S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1193-6 · Cited by 315
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303
Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Advances in Medicine and Biology
Berhardt, L. V. (2017) · International Linear Collider · Cited by 281
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions
Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281
A phosphorylation-acetylation switch regulates STAT1 signaling
Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K.-H., Stauber, R. H., Böhmer, F. D., & Heinzel, T. (2009) · Genes & Development · doi:10.1101/gad.479209 · Cited by 281
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 265
Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Functional Domains of Histone Deacetylase-3
Yang, W.-M., Tsai, S.-C., Wen, Y.-D., Fejér, G., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105993200 · Cited by 248
Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0439-6 · Cited by 246
Epigenetics in cancer: Fundamentals and Beyond
Biswas, S., & Rao, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.011 · Cited by 241
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Liu, L., Chang, H., Chiang, L., & Hung, W. (2003) · PubMed · Cited by 227
Zhang, X., Ozawa, Y., Lee, H., Wen, Y.-D., Tan, T.-H., Wadzinski, B. E., & Seto, E. (2005) · Genes & Development · doi:10.1101/gad.1286005 · Cited by 224
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
Ying, Y., Taori, K., Kim, H., Hong, J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8013727 · Cited by 222
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 222
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 216
Inhibitors of histone deacetylase as antitumor agents: A critical review
Manal, M., Chandrasekar, M. J. N., Gomathi Priya, J., & Nanjan, M. J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.005 · Cited by 216
Wang, D.-F., Helquist, P., Wiech, N. L., & Wiest, O. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0505011 · Cited by 208
Maeda, T., Towatari, M., Kosugi, H., & Saito, H. (2000) · Blood · doi:10.1182/blood.v96.12.3847 · Cited by 207
Dowling, M. L., Voong, K. R., Kim, M., Keutmann, M. K., Harris, E., & Kao, G. D. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1441 · Cited by 204
Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
The N-CoR/Histone Deacetylase 3 Complex Is Required for Repression by Thyroid Hormone Receptor
Ishizuka, T., & Lazar, M. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5122-5131.2003 · Cited by 201
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.9 · Cited by 192
Histone deacetylases and the immunological network: implications in cancer and inflammation
Villagra, A., Sotomayor, E. M., & Seto, E. (2010) · Oncogene · doi:10.1038/onc.2009.334 · Cited by 192
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites
Bougdour, A., Maubon, D., Baldacci, P., Ortet, P., Bastien, O., Bouillon, A., Barale, J.-C., Pelloux, H., Ménard, R., & Hakimi, M.-A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082826 · Cited by 191
Place, R. F., Noonan, E. J., & Giardina, C. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.04.030 · Cited by 189
A SANT motif in the SMRT corepressor interprets the histone code and promotes histone deacetylation
Yu, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg326 · Cited by 180
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions
Hoeksema, M. A., Gijbels, M. J., Van den Bossche, J., van der Velden, S., Sijm, A., Neele, A. E., Seijkens, T., Stöger, J. L., Meiler, S., Boshuizen, M. C., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404170 · Cited by 179
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity
Li, Y., Kao, G. D., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Qin, J., Phelan, C., & Lazar, M. A. (2006) · Genes & Development · doi:10.1101/gad.1455006 · Cited by 176
Cavasin, M. A., Demos-Davies, K., Horn, T. R., Walker, L. A., Lemon, D. D., Birdsey, N., Weiser-Evans, M. C. M., Harral, J., Irwin, D. C., Anwar, A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.258426 · Cited by 175
Zampetaki, A., Zeng, L., Margariti, A., Xiao, Q., Li, H., Zhang, Z., Pepe, A. E., Wang, G., Habi, O., deFalco, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.890491 · Cited by 173
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 169
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Lu, X., Ning, Z., Li, Z., Cao, H., & Wang, X. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01024 · Cited by 166
Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8033763 · Cited by 165
Schrump, D. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2787 · Cited by 165
Kwapis, J. L., Alaghband, Y., Kramár, E. A., López, A. J., Vogel Ciernia, A., White, A. O., Shu, G., Rhee, D., Michael, C. M., Montellier, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05868-0 · Cited by 160
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Self-citationSequence and expression analysis of histone deacetylases in rice
Fu, W., Wu, K., & Duan, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.010 · Cited by 155
Robert, C., & Rassool, F. V. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00003-3 · Cited by 153
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G., Zwinderman, M. R., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 150
Angiolilli, C., Kabala, P. A., Grabiec, A. M., Van Baarsen, I. M., Ferguson, B. S., García, S., Malvar Fernandez, B., McKinsey, T. A., Tak, P. P., Fossati, G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209064 · Cited by 148
Gillespie, J., Savic, S., Wong, C., Hempshall, A., Inman, M., Emery, P., Grigg, R., & McDermott, M. F. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33382 · Cited by 146
Gao, Z., He, Q., Peng, B., Chiao, P. J., & Ye, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507784200 · Cited by 141
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Farhat, D. C., Swale, C., Dard, C., Cannella, D., Ortet, P., Barakat, M., Sindikubwabo, F., Belmudes, L., Bock, P. D., Couté, Y., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0674-4 · Cited by 133
Gupta, M., Han, J. J., Stenson, M., Wellik, L., & Witzig, T. E. (2012) · Leukemia · doi:10.1038/leu.2011.340 · Cited by 132
Inhibitors of Histone Deacetylases
Huber, K., Doyon, G., Plaks, J., Fyne, E., Mellors, J. W., & Sluis-Cremer, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180224 · Cited by 132
Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
Petruccelli, L. A., Dupéré-Richer, D., Pettersson, F., Retrouvey, H., Skoulikas, S., & Miller, W. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020987 · Cited by 131
Rascle, A., Johnston, J. A., & Amati, B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4162-4173.2003 · Cited by 131
Novotny-Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 131
Leus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.010 · Cited by 131
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
Lyu, X., Hu, M., Peng, J., Zhang, X., & Sanders, Y. Y. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862697 · Cited by 130
Xu, Z., Tong, Q., Zhang, Z., Wang, S., Zheng, Y., Liu, Q., Qian, L.-B., Chen, S.-Y., Sun, J., & Cai, L. (2017) · Clinical Science · doi:10.1042/cs20170064 · Cited by 129
Finazzi, G., Vannucchi, A. M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E. M., Olimpieri, O. M., Fioritoni, G., Musolino, C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12332 · Cited by 128
HDAC3 Is a Negative Regulator of Cocaine-Context-Associated Memory Formation
Rogge, G. A., Singh, H., Dang, R., & Wood, M. A. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4472-12.2013 · Cited by 126
Vishwakarma, S., Iyer, L. R., Muley, M. M., Singh, P., Shastry, A., Saxena, A., Kulathingal, J., Vijaykanth, G., Raghul, J., Rajesh, N., et al. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.03.016 · Cited by 124
Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa
Inoue, S., Riley, J., Gant, T. W., Dyer, M. J. S., & Cohen, G. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404760 · Cited by 123
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Zhang, Y., Adachi, M., Kawamura, R., & Imai, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401686 · Cited by 123
HDAC3 overexpression and colon cancer cell proliferation and differentiation
Spurling, C. C., Godman, C. A., Noonan, E. J., Rasmussen, T. P., Rosenberg, D. W., & Giardina, C. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20373 · Cited by 123
Wang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
Venugopal, B., Baird, R., Kristeleit, R. S., Plummer, R., Cowan, R., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 122
Lee, H., Lee, D.-Y., Cho, H., Kim, S.-Y., Iwasaki, Y., & Kim, I. K. (2013) · Circulation Research · doi:10.1161/circresaha.113.301071 · Cited by 121
The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-κB
Ziesché, E., Kettner-Buhrow, D., Weber, A., Wittwer, T., Jurida, L., Soelch, J., Müller, H., Newel, D., Kronich, P., Schneider, H., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks916 · Cited by 121
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells
Condorelli, F., Gnemmi, I., Vallario, A., Genazzani, A. A., & Canonico, P. L. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707608 · Cited by 121
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Self-citationDiscovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Xiao, Y., Wang, J., Zhao, L. Y., Chen, X., Zheng, G., Zhang, X., & Liao, D. (2020) · Chemical Communications · doi:10.1039/d0cc03243c · Cited by 120
Wang, C., Henkes, L. M., Doughty, L. B., He, M., Wang, D., Meyer-Almes, F.-J., & Cheng, Y.-Q. (2011) · Journal of Natural Products · doi:10.1021/np200324x · Cited by 118
ROBBINS, A. R., Jablonski, S. A., Yen, T. J., Yoda, K., Robey, R. W., Bates, S. E., & Sackett, D. L. (2005) · Cell Cycle · doi:10.4161/cc.4.5.1690 · Cited by 118
Neelarapu, R., Holzle, D. L., Velaparthi, S., Bai, H., Brunsteiner, M., Blond, S. Y., & Petukhov, P. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001025 · Cited by 117
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
Martínez-Iglesias, O. A., Ruiz-Llorente, L., Sánchez‐Martínez, R., García, L. D. D., Zambrano, A., & Aranda, A. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0221-x · Cited by 117
Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing
Xu, C., Soragni, E., Chou, C. J., Herman, D., Plasterer, H. L., Rusche, J. R., & Gottesfeld, J. M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.07.010 · Cited by 116
Terui, T., Murakami, K., Takimoto, R., Takahashi, M., Takada, K., Murakami, T., Minami, S., Matsunaga, T., Takayama, T., Kato, J., et al. (2003) · PubMed · Cited by 115
Zhang, X. D., Gillespie, S., Borrow, J. M., & Hersey, P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00509-4 · Cited by 115
Histone deacetylase 3 associates with and represses the transcription factor GATA-2
Ozawa, Y., Towatari, M., Tsuzuki, S., Hayakawa, F., Maeda, T., Miyata, Y., Tanimoto, M., & Saito, H. (2001) · Blood · doi:10.1182/blood.v98.7.2116 · Cited by 113
Synthesis and Biological Activity of Largazole and Derivatives
Seiser, T., Kamena, F., & Cramer, N. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200802043 · Cited by 112
HDAC 3 negatively regulates spatial memory in a mouse model of Alzheimer's disease
Zhu, X., Wang, S., Yu, L., Jin, J., Ye, X., Liu, Y., & Xu, Y. (2017) · Aging Cell · doi:10.1111/acel.12642 · Cited by 112
Hutt, D. M., Roth, D. M., Vignaud, H., Cullin, C., & Bouchecareilh, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106224 · Cited by 109
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 109
Gaymes, T. J., Padua, R. A., Pla, M., Orr, S., Omidvar, N., Chomienne, C., Mufti, G. J., & Rassool, F. V. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0111 · Cited by 108
Jung, S.-B., Kim, C., Naqvi, A., Yamamori, T., Mattagajasingh, I., Hoffman, T. A., Cole, M. P., Kumar, A., DeRicco, J. S., Jeon, B. H., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.222968 · Cited by 108
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 108
Self-citationA phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Batlevi, C. L., Crump, M., Andreadis, C., Rizzieri, D., Assouline, S. E., Fox, S., van der Jagt, R. H. C., Copeland, A., Potvin, D., Chao, R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14698 · Cited by 107
Leng, C., Gries, M., Ziegler, J. A., Lokshin, A. E., Mascagni, P., Lentzsch, S., & Mapara, M. Y. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.014 · Cited by 105
Diet-induced Lethality Due to Deletion of the Hdac3 Gene in Heart and Skeletal Muscle
Sun, Z., Singh, N., Mullican, S. E., Everett, L. J., Li, L., Yuan, L., Liu, X., Epstein, J. A., & Lazar, M. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277707 · Cited by 104
Mishima, Y., Santo, L., Eda, H., Cirstea, D., Nemani, N., Yee, A. J., O'Donnell, E., Selig, M. K., Quayle, S. N., Arastu‐Kapur, S., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13315 · Cited by 103
Gu, L.-Z., Sun, H., & Chen, J. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.094 · Cited by 103
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2820 · Cited by 102
Inhibition of HDAC3 promotes ligand-independent PPARγ activation by protein acetylation
Jiang, X., Ye, X., Guo, W., Lu, H., & Gao, Z. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0066 · Cited by 102
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 101
Hartman, H. B., Yu, J., Alenghat, T., Ishizuka, T., & Lazar, M. A. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400391 · Cited by 101
Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl081 · Cited by 101
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats
Lundh, M., Galbo, T., Poulsen, S. S., & Mandrup‐Poulsen, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12470 · Cited by 100
Li, H., & Wu, X. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.130 · Cited by 100
Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Wells, C. E., Bhaskara, S., Stengel, K. R., Zhao, Y., Sirbu, B., Chagot, B., Cortez, D., Khabele, D., Chazin, W. J., Cooper, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068915 · Cited by 100
Ribrag, V., Kim, W. S., Bouabdallah, R., Lim, S. T., Coiffier, B., Illes, A., Lemieux, B., Dyer, M. J. S., Offner, F., Felloussi, Z., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.154377 · Cited by 97
Пили, Р., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T. E., Shen, L., Orillion, A. R., Lamonica, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1178 · Cited by 97
McClure, J. J., Zhang, C., Inks, E. S., Peterson, Y. K., Li, J., & Chou, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01385 · Cited by 96
Inhibition of Histone Deacetylase 3 Protects Beta Cells from Cytokine-Induced Apoptosis
Chou, D. H.-C., Holson, E. B., Wagner, F. F., Tang, A. J., Maglathlin, R. L., Lewis, T. A., Schreiber, S. L., & Wagner, B. K. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.010 · Cited by 95
Jia, H., Wang, Y., Morris, C. D., Jacques, V., Gottesfeld, J. M., Rusche, J. R., & Thomas, E. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152498 · Cited by 94
Li, X., Peterson, Y. K., Inks, E. S., Himes, R. A., Li, J., Zhang, Y., Kong, X., & Chou, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00136 · Cited by 93
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Yuan, Z., Chen, S., Sun, Q., Wang, N., Li, D., Miao, S., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.058 · Cited by 91
Enantioselective Total Synthesis of (+)-Largazole, a Potent Inhibitor of Histone Deacetylase
Ghosh, A. K., & Kulkarni, S. (2008) · Organic Letters · doi:10.1021/ol8014623 · Cited by 90
Rumbaugh, G., Daws, S. E., Ozkan, E. D., Rojas, C. S., Hubbs, C. R., Aceti, M., Kilgore, M., Kudugunti, S., Puthanveettil, S. V., Sweatt, J. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.93 · Cited by 89
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Godman, C. A., Joshi, R., Tierney, B. R., Greenspan, E., Rasmussen, T. P., Wang, H.-W., Shin, D.-G., Rosenberg, D. W., & Giardina, C. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6561 · Cited by 87
Schmitt, H. M., Pelzel, H. R., Schlamp, C. L., & Nickells, R. W. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-39 · Cited by 86
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86
Lin, W., Zhang, Q., Liu, L., Yin, S., Liu, Z., & Cao, W. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.023 · Cited by 86
Cao, F., de Weerd, S., Chen, D., Zwinderman, M. R. H., van der Wouden, P. E., & Dekker, F. J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112800 · Cited by 86
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
Lewandowski, S. L., Janardhan, H. P., & Trivedi, C. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.684753 · Cited by 85
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102415 · Cited by 85
Shankar, S., Singh, T. R., Fandy, T. E., Luetrakul, T., Ross, D. D., & Srivastava, R. K. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.16.6.1125 · Cited by 83
Histone Deacetylase 3 Is Necessary for Proper Brain Development
Norwood, J., Franklin, J. M., Sharma, D., & D'Mello, S. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.576397 · Cited by 82
Mandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 81
Xia, Y., Wang, J., Liu, T.-J., Yung, W. K. A., Hunter, T. R., & Lu, Z. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.005 · Cited by 80
Hauschild, A., Trefzer, U., Garbe, C., Kaehler, K. C., Ugurel, S., Kiecker, F., Eigentler, T., Krissel, H., Schott, A., & Schadendorf, D. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307c248 · Cited by 79
Suelves, N., Kirkham-McCarthy, L., Lahue, R. S., & Ginés, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05125-2 · Cited by 79
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection
Barton, K. M., Archin, N. M., Keedy, K. S., Espeseth, A. S., Zhang, Y.-L., Gale, J., Wagner, F. F., Holson, E. B., & Margolis, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102684 · Cited by 76
Li, X., Inks, E. S., Li, X., Hou, J., Chou, C. J., Zhang, J., Jiang, Y., Zhang, Y., & Xu, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401877m · Cited by 76
Nasveschuk, C. G., Ungermannova, D., Liu, X., & Phillips, A. J. (2008) · Organic Letters · doi:10.1021/ol8013478 · Cited by 75
HDAC3 inhibition ameliorates spinal cord injury by immunomodulation
Kuboyama, T., Wahane, S., Huang, Y., Zhou, X., Wong, J. K., Koemeter-Cox, A., Martini, M., Friedel, R. H., & Zou, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-08535-4 · Cited by 74
Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 74
Self-citationKim, H.-C., Choi, K., Choi, H., Kang, H., Kim, M., Lee, Y., Lee, O., Lee, J., Kim, Y. J., Jun, W., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0388-5 · Cited by 73
Ho, M., Chen, T., Liu, J., Dowling, P., Hideshima, T., Zhang, L., Morelli, E., Camci-Unal, G., Wu, X., Tai, Y.-T., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0493-x · Cited by 73
Sharifi‐Sanjani, M., Shoushtari, A. H., Quiroz, M. E., Baust, J., Sestito, S. F., Mosher, M., Ross, M., McTiernan, C. F., Croix, C. M. S., Bilonick, R. A., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000670 · Cited by 72
Improving Insulin Sensitivity With HDAC Inhibitor
Ye, J. (2013) · Diabetes · doi:10.2337/db12-1354 · Cited by 71
Li, S., Fossati, G., Marchetti, C., Modena, D., Pozzi, P., Reznikov, L. L., Moras, M. L., Azam, T., Abbate, A., Mascagni, P., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618454 · Cited by 69
Maubon, D., Bougdour, A., Wong, Y.-S., Brenier-Pinchart, M.-P., Curt, A., Hakimi, M.-A., & Pelloux, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-10 · Cited by 69
Estella, C., Herrer, I., Atkinson, S. P., Quiñonero, A., Martínez, S., Pellicer, A., & Simón, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030508 · Cited by 68
Chen, J., Li, N., Liu, B., Ling, J., Yang, W., Pang, X., & Li, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117469 · Cited by 68
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein
Kim, Y., Kim, K., Park, D., Lee, E.-M., Lee, H., Lee, Y., Choe, J., & Jeoung, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348284 · Cited by 67
Escaffit, F., Vaute, O., Chevillard-Briet, M., Segui, B., Takami, Y., Nakayama, T., & Trouche, D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00869-06 · Cited by 67
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors
Hsieh, H.-Y., Chuang, H.-C., Shen, F.-H., Detroja, K., Hsin, L.-W., & Chen, C.-S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.069 · Cited by 67
He, R., Chen, Y., Chen, Y., Ougolkov, A. V., Zhang, J.-S., Savoy, D. N., Billadeau, D. D., & Kozikowski, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901667k · Cited by 66
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
Kumar, S. K., Tandon, N., & Ramakrishnan, V. G. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s94021 · Cited by 66
Li, X., Jiang, Y., Peterson, Y. K., Xu, T., Himes, R. A., Luo, X., Yin, G., Inks, E. S., Dolloff, N., Halene, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00442 · Cited by 66
The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage
Wang, H., Zhou, W., Zheng, Z., Zhang, P., Tu, B., He, Q., & Zhu, W. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.10.014 · Cited by 65
Yao, Y., Tu, Z., Liao, C., Wang, Z., Li, S., Yao, H., Li, Z., & Jiang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01044 · Cited by 65
Child, F. J., Ortiz-Romero, P. L., Alvarez, R., Bagot, M., Stadler, R., Weichenthal, M., Alves, R., Quaglino, P., Beylot-Barry, M., Cowan, R. A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14427 · Cited by 65
Krishna, K., Behnisch, T., & Sajikumar, S. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150838 · Cited by 64
Li, Z., Li, Q.-Z., Chen, L., Chen, B.-D., Wang, B., Zhang, X., & Li, W.-P. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2043-5 · Cited by 64
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer
Hu, G., He, N., Cai, C., Cai, F., Fan, P., Zheng, Z., & Jin, X. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.011 · Cited by 64
Moumné, L., Campbell, K., Howland, D., Ouyang, Y., & Bates, G. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031080 · Cited by 63
Nawrocki, S. T., Carew, J. S., Douglas, L., Cleveland, J. L., Humphreys, R. C., & Houghton, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0812 · Cited by 62
Trivedi, P., Adhikari, N., Amin, S. A., Jha, T., & Ghosh, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.030 · Cited by 62
Self-citationDávalos-Salas, M., Montgomery, M. K., Reehorst, C. M., Nightingale, R., Ng, I., Anderton, H., Al-Obaidi, S., Lesmana, A., Scott, C. M., Ioannidis, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13180-8 · Cited by 62
Al‐Yacoub, N., Fecker, L. F., Möbs, M., Plötz, M., Braun, F., Sterry, W., & Eberle, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.125 · Cited by 61
Zhang, H., Ji, L., Yang, Y., Wei, Y., Zhang, X., Gang, Y., Lu, J., & Bai, L. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01060 · Cited by 61
Yang, X., Wu, Q., Zhang, L., & Feng, L. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00131 · Cited by 60
Zhao, B., Yuan, Q., Hou, J.-B., Xia, Z.-Y., Zhan, L.-Y., Li, M., Jiang, M., Gao, W.-W., & Liu, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8520856 · Cited by 60
Research works printed but not linked: 3
- Liu L. T., 2003, Cancer Res., 63, 3069
- Terui T., 2003, Cancer Res., 63, 8948
- Xu Y., 2005, Int. J. Mol. Med., 15, 169
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
“Interestingly, in HPLC-based assay with myristoyl-H3K9 peptide as substrate, SIS17 (25) are slightly less potent than FT895 (24).”
BackgroundMethodInfluentialCarboranes as unique pharmacophores in antitumor medicinal chemistry
Chen, Y., Du, F., Tang, L., Xu, J., Zhao, Y., Wu, X., Li, M., Shen, J., Wen, Q., Cho, C. H., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.005 · Cited by 135
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Self-citationThe role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
He, R., Liu, B., Geng, B., Li, N., & Geng, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01399-w · Cited by 75
“The unique structure of HDAC3 All class I HDAC enzymes exhibit structural similarity to reduced potassium depenency 3 (RPD3) in yeast, and mainly contain a catalytic core domain and C-and N-terminals [17].”
Metadata
- Authors
- Adhikari, N., Jha, T., & Ghosh, B.
- Affiliations
- Jadavpur University (IN)
- Birla Institute of Technology and Science - Hyderabad Campus (IN)
- Corresponding author
- Jha, Tarun
- Ghosh, Balaram
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-06-23
- Volume
- 64
- Issue
- 13
- Pages
- 8827-8869
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3176448552
- Cited by
- 74
- References
- 308
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 18 · 2023: 15 · 2022: 8 · 2021: 3
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Council of Scientific and Industrial Research (09/096(0966)/2019-EMR-I, CSIR- 37(1722)/19/EMR-II)
- University Grants Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HDAC3, histone acetylation, non-histone protein acetylation, epigenetic drug targets, cancer, neurodegenerative diseases, diabetes mellitus, obesity, cardiovascular disease, autoimmune disease, inflammatory diseases, parasitic infection, HIV, inhibitor design
- MeSH terms
- Histone Deacetylase 3, Autoimmune Diseases, Cardiovascular Diseases, Diabetes Mellitus, Histone Deacetylases, Humans, Neoplasms, Obesity, HIV Infections, Neurodegenerative Diseases, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.